Volker A Coenen1, Florian Amtage, Jens Volkmann, Thomas E Schläpfer. 1. Abteilung Stereotaktische und Funktionelle Neurochirurgie, Universitätsklinikum der Albert-Ludwigs-Universität Freiburg, Klinik für Neurologie und Neurophysiologie, Albert-Ludwigs-Universität Freiburg, Neurologische Klinik und Poliklinik, Universit7auml;sklinikum Würzburg, Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum.
Abstract
BACKGROUND: Deep brain stimulation (DBS) is the chronic electrical stimulation of selected target sites in the brain through stereotactically implanted electrodes. More than 150 000 patients around the world have been treated to date with DBS for medically intractable conditions. The indications for DBS include movement disorders, epilepsy, and some types of mental illness. METHODS: This review is based on relevant publications retrieved by a selective search in PubMed and the Cochrane Library, and on the current guidelines of the German Neurological Society (Deutsche Gesellschaft für Neurologie, DGN). RESULTS: DBS is usually performed to treat neurological diseases, most often movement disorders and, in particular, Parkinson's disease. Multiple randomized controlled trials (RCTs) have shown that DBS improves tremor, dyskinesia, and quality of life in patients with Parkinson's disease by 25% to 50%, depending on the rating scales used. DBS for tremor usually involves stimulation in the cerebello-thalamo-cortical regulatory loop. In an RCT of DBS for the treatment of primary generalized dystonia, the patients who underwent DBS experienced a 39.3% improvement of dystonia, compared to only 4.9% in the control group. Two multicenter trials of DBS for depression were terminated early because of a lack of efficacy. CONCLUSION: DBS is an established treatment for various neurological and psychiatric diseases. It has been incorporated in the DGN guidelines and is now considered a standard treatment for advanced Parkinson's disease. The safety and efficacy of DBS can be expected to improve with the application of new technical developments in electrode geometry and new imaging techniques. Controlled trials would be helpful so that DBS could be extended to further indications, particularly psychiatric ones.
BACKGROUND: Deep brain stimulation (DBS) is the chronic electrical stimulation of selected target sites in the brain through stereotactically implanted electrodes. More than 150 000 patients around the world have been treated to date with DBS for medically intractable conditions. The indications for DBS include movement disorders, epilepsy, and some types of mental illness. METHODS: This review is based on relevant publications retrieved by a selective search in PubMed and the Cochrane Library, and on the current guidelines of the German Neurological Society (Deutsche Gesellschaft für Neurologie, DGN). RESULTS: DBS is usually performed to treat neurological diseases, most often movement disorders and, in particular, Parkinson's disease. Multiple randomized controlled trials (RCTs) have shown that DBS improves tremor, dyskinesia, and quality of life in patients with Parkinson's disease by 25% to 50%, depending on the rating scales used. DBS for tremor usually involves stimulation in the cerebello-thalamo-cortical regulatory loop. In an RCT of DBS for the treatment of primary generalized dystonia, the patients who underwent DBS experienced a 39.3% improvement of dystonia, compared to only 4.9% in the control group. Two multicenter trials of DBS for depression were terminated early because of a lack of efficacy. CONCLUSION: DBS is an established treatment for various neurological and psychiatric diseases. It has been incorporated in the DGN guidelines and is now considered a standard treatment for advanced Parkinson's disease. The safety and efficacy of DBS can be expected to improve with the application of new technical developments in electrode geometry and new imaging techniques. Controlled trials would be helpful so that DBS could be extended to further indications, particularly psychiatric ones.
Authors: Jens Kuhn; Theo O J Gründler; Doris Lenartz; Volker Sturm; Joachim Klosterkötter; Wolfgang Huff Journal: Dtsch Arztebl Int Date: 2010-02-19 Impact factor: 5.594
Authors: Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda Journal: N Engl J Med Date: 2010-06-03 Impact factor: 91.245
Authors: Andreas Kupsch; Reiner Benecke; Jörg Müller; Thomas Trottenberg; Gerd-Helge Schneider; Werner Poewe; Wilhelm Eisner; Alexander Wolters; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger Marie Skogseid; Geir Ketil Roeste; Juliane Vollmer-Haase; Angela Brentrup; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Markus Naumann; Jens Volkmann Journal: N Engl J Med Date: 2006-11-09 Impact factor: 91.245
Authors: Anne Koy; Martin Hellmich; K Amande M Pauls; Warren Marks; Jean-Pierre Lin; Oliver Fricke; Lars Timmermann Journal: Mov Disord Date: 2013-02-13 Impact factor: 10.338
Authors: P Amami; I Dekker; S Piacentini; F Ferré; L M Romito; A Franzini; E M J Foncke; A Albanese Journal: J Neurol Neurosurg Psychiatry Date: 2014-07-10 Impact factor: 10.154
Authors: Thomas E Schläpfer; Andreas Meyer-Lindenberg; Matthis Synofzik; Veerle Visser-Vandewalle; Jürgen Voges; Volker A Coenen Journal: Dtsch Arztebl Int Date: 2021-01-22 Impact factor: 5.594
Authors: Danesh Ashouri Vajari; Maria Vomero; Johannes B Erhardt; Ali Sadr; Juan S Ordonez; Volker A Coenen; Thomas Stieglitz Journal: Micromachines (Basel) Date: 2018-10-10 Impact factor: 2.891
Authors: Maurizio Gulino; Donghoon Kim; Salvador Pané; Sofia Duque Santos; Ana Paula Pêgo Journal: Front Neurosci Date: 2019-07-05 Impact factor: 4.677
Authors: Volker A Coenen; Máté D Döbrössy; Shi Jia Teo; Johanna Wessolleck; Bastian E A Sajonz; Peter C Reinacher; Annette Thierauf-Emberger; Björn Spittau; Jochen Leupold; Dominik von Elverfeldt; Thomas E Schlaepfer; Marco Reisert Journal: Brain Struct Funct Date: 2021-09-05 Impact factor: 3.270
Authors: Krzysztof A Bujarski; Yinchen Song; Tiankang Xie; Zachary Leeds; Sophia I Kolankiewicz; Gabriella H Wozniak; Sean Guillory; Joshua P Aronson; Luke Chang; Barbara C Jobst Journal: Front Neurosci Date: 2022-02-09 Impact factor: 4.677